Keywords: repligen, fy, sees, sales, rise, biopharmaceutical, group
Repligen's FY 2005 sees 35% sales rise
Article | 06 June 2005
US biopharmaceutical group Repligen says that its total revenue for the fiscal year ended March 31, 2005, was $9.36 million versus $6.91 miliion for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
